Primary |
Sinusitis |
16.7% |
Product Used For Unknown Indication |
14.8% |
Pneumonia |
10.3% |
Bronchitis |
9.0% |
Drug Use For Unknown Indication |
7.6% |
Urinary Tract Infection |
7.6% |
Infection |
5.2% |
Upper Respiratory Tract Infection |
3.5% |
Bacterial Infection |
3.4% |
Hypertension |
2.7% |
Asthma |
2.6% |
Pain |
2.3% |
Chronic Obstructive Pulmonary Disease |
2.2% |
Diverticulitis |
2.1% |
Respiratory Tract Infection |
2.0% |
Ill-defined Disorder |
1.9% |
Diabetes Mellitus |
1.6% |
Blood Pressure |
1.6% |
Prostatitis |
1.5% |
Kidney Infection |
1.2% |
|
Tendonitis |
21.7% |
Tendon Rupture |
21.2% |
Rotator Cuff Syndrome |
9.5% |
Pain In Extremity |
6.0% |
Tendon Disorder |
5.6% |
Tendon Pain |
5.1% |
Tenosynovitis |
4.4% |
Urticaria |
2.9% |
Weight Decreased |
2.7% |
Vomiting |
2.6% |
Tremor |
2.5% |
Pain |
2.1% |
Tendon Injury |
2.1% |
Rash |
2.0% |
Meniscus Lesion |
1.9% |
Paraesthesia |
1.8% |
Arthralgia |
1.6% |
Joint Injury |
1.4% |
Tenosynovitis Stenosans |
1.4% |
Myalgia |
1.3% |
|
Secondary |
Product Used For Unknown Indication |
17.1% |
Sinusitis |
11.7% |
Bronchitis |
8.8% |
Urinary Tract Infection |
6.8% |
Pneumonia |
6.1% |
Bronchitis Chronic |
5.9% |
Lower Respiratory Tract Infection |
5.9% |
Upper Respiratory Tract Infection |
5.2% |
Asthma |
4.5% |
Infection |
3.8% |
Bacterial Infection |
3.7% |
Chronic Obstructive Pulmonary Disease |
3.2% |
Diverticulitis |
3.1% |
Drug Use For Unknown Indication |
3.0% |
Hypertension |
2.3% |
Pain |
2.1% |
Ill-defined Disorder |
2.0% |
Cough |
1.6% |
Staphylococcal Infection |
1.6% |
Diabetes Mellitus |
1.6% |
|
Tendon Rupture |
19.1% |
Rotator Cuff Syndrome |
19.0% |
Tendonitis |
18.6% |
Tenosynovitis |
9.3% |
Tendon Disorder |
5.5% |
Drug Hypersensitivity |
3.2% |
Urticaria |
2.7% |
Tendon Pain |
2.4% |
Thinking Abnormal |
2.3% |
Pain In Extremity |
1.8% |
Tendon Injury |
1.8% |
Weight Decreased |
1.8% |
Trigger Finger |
1.7% |
Plantar Fasciitis |
1.7% |
Toxic Epidermal Necrolysis |
1.6% |
Vomiting |
1.6% |
Depression |
1.5% |
Epicondylitis |
1.5% |
Tenosynovitis Stenosans |
1.5% |
Ligament Rupture |
1.4% |
|
Concomitant |
Product Used For Unknown Indication |
33.8% |
Drug Use For Unknown Indication |
22.0% |
Pain |
7.0% |
Multiple Myeloma |
5.5% |
Hypertension |
3.9% |
Depression |
2.9% |
Asthma |
2.4% |
Nausea |
2.4% |
Prophylaxis |
2.3% |
Breast Cancer |
2.2% |
Contraception |
2.2% |
Anxiety |
2.1% |
Gastrooesophageal Reflux Disease |
1.9% |
Osteoporosis |
1.7% |
Diabetes Mellitus |
1.4% |
Pneumonia |
1.3% |
Urinary Tract Infection |
1.3% |
Constipation |
1.2% |
Metastases To Bone |
1.2% |
Insomnia |
1.2% |
|
Vomiting |
15.8% |
Weight Decreased |
13.6% |
Pulmonary Embolism |
9.7% |
Urinary Tract Infection |
7.3% |
Pneumonia |
6.4% |
Pain |
5.0% |
Weight Increased |
4.8% |
White Blood Cell Count Decreased |
4.7% |
Thrombocytopenia |
3.8% |
Respiratory Failure |
3.0% |
Pyrexia |
3.0% |
Sepsis |
2.8% |
Death |
2.8% |
Wheezing |
2.8% |
Deep Vein Thrombosis |
2.6% |
Type 2 Diabetes Mellitus |
2.5% |
Myocardial Infarction |
2.4% |
Dyspnoea |
2.4% |
Thrombosis |
2.3% |
Injury |
2.3% |
|
Interacting |
Drug Use For Unknown Indication |
15.1% |
Hypertension |
15.1% |
Chronic Sinusitis |
14.3% |
Convulsion |
10.3% |
Sinusitis |
6.3% |
Atrial Fibrillation |
4.0% |
Blood Pressure Abnormal |
4.0% |
Ingrowing Nail |
4.0% |
Asthma |
2.4% |
Cerebrovascular Accident Prophylaxis |
2.4% |
Depression |
2.4% |
Diabetes Mellitus |
2.4% |
Epilepsy |
2.4% |
Flushing |
2.4% |
Heart Rate Abnormal |
2.4% |
Infection |
2.4% |
Renal Disorder |
2.4% |
Urinary Tract Infection |
2.4% |
Aspergillosis |
1.6% |
Chronic Myeloid Leukaemia |
1.6% |
|
Tendon Rupture |
20.5% |
Drug Interaction |
13.6% |
Sinusitis |
13.6% |
Urinary Tract Infection |
6.8% |
Neoplasm Malignant |
4.5% |
Swelling Face |
4.5% |
Syncope |
4.5% |
Upper Respiratory Tract Infection |
4.5% |
Dizziness |
2.3% |
Feeling Abnormal |
2.3% |
Headache |
2.3% |
Hypertension |
2.3% |
Loss Of Consciousness |
2.3% |
Myalgia |
2.3% |
Oedema Peripheral |
2.3% |
Palpitations |
2.3% |
Pneumonia |
2.3% |
Pulmonary Embolism |
2.3% |
Rash Generalised |
2.3% |
Tachypnoea |
2.3% |
|